Elotuzumab in combination with dose reduced IMiDs and dexamethasone for AL amyloidosis patients with relapsed/refractory plasma cell dyscrasia and advanced organ involvement - Dittrich, Tobias; Hansen, Timon; Kimmich, Christoph; Veelken, Kaya; Jauch, Anna Sophia; Raab, Marc-Steffen; Müller-Tidow, Carsten; Hegenbart, Ute; Schönland, Stefan (American journal of hematology, 2025)
Online veröffentlicht: 25. April 2025